Podcast 29 Aug 2025A Finnish biotech is making progress on Parkinson’s disease with support from The Michael J. Fox Foundation Our guest this week is Antti Vuolanto, CEO of Herantis Pharma, and we discussed the science behind their approach, and the advantages and challenges of working in biotech in the Nordics. August 29, 2025 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
Best in Biotech 23 May 2025 Finland: Pushing biotech forward in the land of a thousand lakes Explore seven leading biotech companies driving Finland’s biotech sector forward in precision medicine, immunotherapy, and more. May 23, 2025 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2023 Finnish biotech startup Solu raises €1M to combat global antibiotic resistance Solu, founded in 2022, is a Finnish biotechnology company focusing on combating antibiotic resistance by building the world’s most extensive pathogen DNA library. Solu’s product makes understanding, detecting, and preventing the spread of antibiotic resistance easier and enables real-time monitoring to detect dangerous mutations effectively. The company has recently received seed funding of €1 million […] June 15, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2023 New study reveals Alzheimer’s inflammation protection A possible explanation has been found in a study for why apoE4, the most significant genetic risk factor associated with Alzheimer’s disease, fails to protect the brain from inflammation.Alzheimer’s disease is characterized by the accumulation of plaques of the amyloid-β protein, chronic inflammation and impaired neuronal function in the brain. The most significant genetic risk […] May 30, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2023 Researchers identify gene expression signature to predict progression of type 1 diabetes Researchers from Turku Bioscience Centre and InFLAMES Flagship at the University of Turku in Finland, have identified a gene expression signature that can predict the progression of type 1 diabetes.The study, led by Laura Elo and Riitta Lahesmaa, aimed to identify transcriptional changes associated with disease progression in patients with recent-onset type 1 diabetes. The […] May 30, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 May 2023 Researchers discover genetic variation offers Alzheimer’s disease clues A new study conducted by researchers at the University of Eastern Finland discovered that the APP A673T genetic variant, which protects against Alzheimer’s disease (AD), alters levels of several proteins and peptides linked to amyloid-beta metabolism in human biofluids and cell culture models, including amyloid beta itself. These new data support the idea that even […] May 25, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 May 2023 Alzheimer’s drugs could result from immune brain cell discovery A recent study published in Nature Neuroscience indicates that, contrary to common belief, the immune cells of the brain, known as microglia, are not all the same. Researchers found that a unique microglial subset with unique features and function is important for establishing proper cognitive functions in mice. Evidence for such microglial subsets exists also […] May 15, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Mar 2023 Gut microbiota to be harnessed as a tool to diagnose diseases A recent study at the University of Jyväskylä in Finland compared the gut microbiota and gut-derived metabolites between healthy controls and individuals with fatty liver. The results revealed that certain microbial metabolites are associated with liver fat content. The fact that the gut microbiota associates with many diseases has raised the hope that they could […] March 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Feb 2023 New promising targeted drug for a rare leukemia Targeted drugs have been developed to supplement chemotherapy in the treatment of cancer. These drugs only affect cancer cells, leaving healthy cells alone. Venetoclax is a new targeted therapy option for the treatment of acute myeloid leukemia (AML). It was recently granted marketing authorization in Finland. Venetoclax works by sensitizing cancer cells to programmed cell […] February 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Feb 2023 TILT Biotherapeutics closes €22M financing for oncology immunotherapy trials TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, has closed its €22 million ($23.8 million) round. This follows on from the first close of €10 million in June 2022. The financing was led by Finland’s Lifeline Ventures, an early-stage venture capital firm founded by serial entrepreneurs. The funding will be used to advance […] February 9, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jan 2023 Hundreds of genetic discoveries from FinnGen study New results from the FinnGen research consortium include previously unknown genetic risk factors for many debilitating diseases. These findings have potential to facilitate the development of new therapies. Since initiation in 2017, the FinnGen study has developed into one of the world’s leading biobank-based genomic research projects. Currently, FinnGen is completing the construction of a […] January 19, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2022 Watch: Valo Therapeutics at Bio-Europe Valo Therapeutics Oy is a Finnish immunotherapy company developing antigen-coated oncolytic viruses and vaccine vectors as innovative immunotherapy approaches against cancer and infectious disease. The Valo Therapeutics lead platform, PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus), was developed at the laboratory of Vincenzo Cerullo at the University of Helsinki in Finland. It turns oncolytic adenoviruses into targeted […] December 20, 2022 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email